Member Info for Bella6532

Down side relating to her previous companies tech...'Despite impressive advances, there are multiple outstanding challenges with NK cell therapies. Methods following good manufacturing practices to generate large clinical doses from a single healthy donor and selective expansion appropriate NK cell subsets with best predictive KIR/HLA are needed. Additionally, tumor immune evasion remains a large barrier. Once the NK or CAR-NK cells are infused into the patient, the long-term persistence of these cells in-vivo in the tumor microenvironment needs to be ensured and monitored. Another limitation with NK and CAR-NK cells is the memory property in vivo, which is not fully understood as in the case of memory T cells in adaptive immunity. Identifying novel CAR targets and generation of NK specific CAR constructs will enable CAR-NK cell homing and persistence in solid tumors contributing to breakthrough approaches driving allogeneic NK therapies towards the next frontier of cancer immunotherapy.'

Https://www.cytoimmune.com/our-science/

Timster...'She's not made that move into a company on the verge of failure.'...agree...

She's just left a CEO potion in small company in early stage trials...why make the move to Avacta. Is it purely based on a move back to UK or is Avacta trial data far more attractive than that of the company she just left. We've announced her appoingment but her last company doesn't appear to have announced her leaving...

I've mention the above because this apppointment might be much bigger than we think if she believes the PreCision will be better for patient treatment/outcomes than what she's just been involved in...mmmm!!!

"I am thrilled to join the team during such a pivotal time for the company as we move our game-changing pipeline forward for the benefit of patients."

Another indication it works...she would know...

Bullseye43...when we get the next Qrtly repayment RNS I'll put up some numbers and hopefully someone will come up with some answers...I have my own theory but let's see what we get on Monday.

18-Jan-24 15:40:46 104.00 175,000 Sell* 104.00 105.00 182.00k

RMFatGB...'Waiting the next RNS from Avacta with anticipation.'

The next RNS should be on Monday covering the Qrtly repayment/share issue...

Livedataaccount...difference between II's and PI's

II's load up as price goes down ready to sell to PI's who load up as price rises.

The Therapeutics side of Avacta needs to grow it's income stream and get published efficacy data for AVA6000. The DX side also needs to grow and get ride of it's debt. Thst's what the markets are looking for...that's it...income/profits...bla bla

Now if we get a partnership or AA deal or licence deal which basically fully funds AVA6000 upfront going forward and basically allows the debt to be paid off then that will wake the markets up too...

Timster...haha...we all think we know stuff...even you...wink...

Timster...they are guessing like the rest of us...they are mere mortals too. Once we get the next qrtly payment details I will pose you a question about it...hopefully you will be able to answer it and clear a little gals confusion...

Hang on...his Drum Roll was about sizeable buy incoming...no mention of an RNS...

Mmm...if they get shares at 94.5 to 95.4 then the price was locked at yesterdays low or close less 10%

Page 2

Oh and then there's

“If AVA3996 is shown to have a significantly improved safety profile in the clinic, then not only could it provide a better tolerated treatment for multiple myeloma, but it has the potential to be the first proteasome inhibitor to be suitable for treating solid tumours, thereby significantly increasing the market opportunity.”

Oh and as fas a JNJ is concerned:

“Our multiple myeloma portfolio is the most important driver of growth for our pharmaceutical group moving forward.”

J&J sells the multiple myeloma treatment Darzalex, which has become a mainstay in treatment regimens for the blood cancer.

https://www.biopharmadive.com/news/johnson-johnson-cancer-drug-sales-pharma-4q22/641071/

Apr 6, 2015

'J&J is Pharmacyclics' partner on the blood cancer drug Imbruvica, a fast-growing therapy in a hot field. It's a partnership that J&J struck years ago, at a cost of some $975 million, plus a split of eventual profits. Last month, AbbVie ($ABBV) agreed to buy Pharmacyclics--including its share of Imbruvica and some pipeline meds--for $21 billion.

The price stunned many analysts at the time, and Gorsky used the familiar words "thoughtful" and "disciplined" in answering the WSJ's question. The vast majority of J&J's acquisitions over the past 10 years--more than 100 in all--have been under $1 billion, the CEO said.

"Most of our investments tend to be early-on, smaller, midsize," Gorsky told the Journal. "Occasionally we'll go big as we did when we went after Synthes not too long ago.

"But in the pharma space, identifying another Zytiga, identifying the next Imbruvica is something that we're very interested in."

In other words, buy low, sell high. In biopharma, that means risk--there's no guarantee, of course, that pipeline drugs will actually pay off as hoped--but it also means less of a write down if expectations aren't met down the road. And J&J's team has a strong track record of picking winners.'

https://www.fiercepharma.com/m-a/why-didn-t-j-j-buy-imbruvica-partner-pharmacyclics-it-wants-hot-drugs-cheap-ceo-says

Now move forward to recent events...

'The slew of news from the JP Morgan Healthcare conference that started this morning started with a trio of takeover deals from Johnson & Johnson, Novartis, and MSD.

J&J’s $2 billion play for Californian antibody-drug conjugate (ADC) specialist Ambrx is the largest of the three, and came alongside confirmation of a rumoured takeover of Harpoon Therapeutics and its T-cell engager pipeline by MSD – now confirmed at $680 million – and a $425 million offer by Novartis for Calypso Biotech and its antibody drug for autoimmune diseases.'

https://pharmaphorum.com/news/jpm-kicks-takeovers-jj-novartis-and-msd

They're all piling into ADC's like lemmings...

Right now the space for the likes of AVA6000 is with a manufacturer of Dox...

Doxorubicin Market Leaders

Pfizer Inc.

Johnson and Johnson (Janssen Pharmaceutical)

Zydus Group

Cipla Limited

Sun Pharmaceutical Industries Ltd

https://www.mordorintelligence.com/industry-reports/doxorubicin-market

So if JNJ are still interested in new and innovative tech on the cheap then why not Avacta's AVA6000 and do a deal like the one above. By offering Dox without side effects they would blast the compeition our of the water and this could be done with one simple itsy bitsy produce.

Come on JNJ...cut the deals and let's get the show on the road so people can at least benefit from much higher doses of Dox without the debilitating side effect.

Cont P2

Cj62..'What AS has up his sleeve is a mystery but let's hope its something that avoids a cash raise.'

He's not worried and said we shouldn't worry either...

Https://avacta.com/2017-08-03/

And affimers for imaging/diagnostics explained here too...

Explained here..

https://pubmed.ncbi.nlm.nih.gov/35848463/

Https://www.cnbc.com/2024/01/14/cancer-drugs-renewed-interest-in-adcs-will-continue-in-2024.html

'Summary

By using multiple ligand discovery platforms, affinity adsorbents for a diverse range of target molecules

from complex feedstocks have been developed.

The Synthetic Library and Affimer® library technology provide different advantages that can be

exploited to meet diverse ligand criteria required for successful affinity adsorbent development'

WeAreGroot...sorry that link post was a bit tongue in cheek on my part.